利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.017 秒)

    ANTIBODIES SPECIFIC FOR IL-17A FUSED TO HYALURONAN BINDING PEPTIDE TAGS
    1.
    发明公开
    ANTIBODIES SPECIFIC FOR IL-17A FUSED TO HYALURONAN BINDING PEPTIDE TAGS 审中-公开
    与透明质酸结合肽标签融合的IL-17A特异性抗体

    公开(公告)号：EP3161001A2

    公开(公告)日：2017-05-03

    申请号：EP15741338.6

    申请日：2015-06-23

    申请人： Novartis AG

    发明人： DI PADOVA, Franco E. ,  GHOSH, Joy ,  HUBER, Thomas ,  RONDEAU, Jean-Michel Rene

    IPC分类号： C07K16/24 ,  A61K39/395 ,  C07K14/47 ,  A61K39/00

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K47/48546 ,  A61K2039/505 ,  C07K14/47 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/20 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/35 ,  C07K2319/70

    摘要： The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A and a peptide tag that binds hyaluronan (HA). The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL-17A and IL-17AF) and are capable of inhibiting IL-17A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

    摘要翻译： 本公开涉及抗体和蛋白质，其包含特异性结合促炎细胞因子IL-17A的抗原结合部分和结合透明质酸（HA）的肽标签。 本公开更具体地涉及作为IL-17A拮抗剂（抑制IL-17A和IL-17AF的活性）并且能够在体外测定中抑制IL-17A诱导的细胞因子产生并且具有抑制作用的特异性抗体和蛋白质 在体内抗原诱导的关节炎模型中。 本公开还涉及用于所述抗体和蛋白质以治疗可通过抑制IL-17A或IL17AF介导的活性（例如类风湿性关节炎，牛皮癣，系统性红斑狼疮（SLE），狼疮肾炎等）治疗的病理学病症的组合物和方法。 慢性阻塞性肺病，哮喘或囊性纤维化或其他自身免疫性和炎症性疾病。

    ANTIBODIES DIRECTED TO ANGIOPOIETIN-LIKE PROTEIN 4 AND USES THEREOF
    5.
    发明公开
    ANTIBODIES DIRECTED TO ANGIOPOIETIN-LIKE PROTEIN 4 AND USES THEREOF 有权
    GEGEN ANGIOPOIETIN-like蛋白4 GERICHTETEANTIKÖRPERUND IHRE VERWENDUNG

    公开(公告)号：EP2007899A4

    公开(公告)日：2009-07-08

    申请号：EP07753609

    申请日：2007-03-20

    申请人： CURAGEN CORP ,  AMGEN FREMONT INC

    发明人： ZHONG HAIHONG ,  ZHOU QING

    IPC分类号： C12P21/08 ,  A61K39/395 ,  C07H21/04 ,  C07K16/00 ,  C12N5/06 ,  C12N15/02 ,  C12P21/04 ,  G01N33/53 ,  G01N33/574

    CPC分类号： C07K16/22 ,  A61K47/48546 ,  A61K47/6845 ,  A61K51/1021 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57488

    摘要： Antibodies directed to the antigen ANGPTL4 and uses of such antibodies. In accordance with the teachings herein, there are provided fully human monoclonal antibodies directed to the antigen ANGPTL4. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

    摘要翻译： 针对抗原ANGPTL4的抗体和这种抗体的用途。 根据本文的教导，提供针对抗原ANGPTL4的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 ，被提供。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

    ANTIBODIES DIRECTED TO ANGIOPOIETIN-LIKE PROTEIN 4 AND USES THEREOF
    7.
    发明授权
    ANTIBODIES DIRECTED TO ANGIOPOIETIN-LIKE PROTEIN 4 AND USES THEREOF 有权
    GEGEN ANGIOPOIETIN-like PROTEIN 4 GERICHTETEANTIKÖRPERUND IHRE VERWENDUNG

    公开(公告)号：EP2007899B1

    公开(公告)日：2017-06-07

    申请号：EP07753609

    申请日：2007-03-20

    申请人： CELLDEX THERAPEUTICS INC ,  AMGEN FREMONT INC

    发明人： ZHONG HAIHONG ,  ZHOU QING

    IPC分类号： C07K16/30 ,  A61K39/00 ,  A61K47/68 ,  A61K51/10 ,  C07K16/22 ,  G01N33/574

    CPC分类号： C07K16/22 ,  A61K47/48546 ,  A61K47/6845 ,  A61K51/1021 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57488

    摘要： Antibodies directed to the antigen ANGPTL4 and uses of such antibodies. In accordance with the teachings herein, there are provided fully human monoclonal antibodies directed to the antigen ANGPTL4. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

    摘要翻译： 针对抗原ANGPTL4的抗体和这些抗体的用途。 根据本文的教导，提供了针对抗原ANGPTL4的完全人类单克隆抗体。 编码核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR's）的连续重链和轻链序列的序列，特别是FR1至FR4或CDR1至CDR3 ，提供。 还提供了表达此类免疫球蛋白分子和单克隆抗体的杂交瘤或其他细胞系。